PILA PHARMA TO PARTICIPATE AT THE 61ST EASD DIABETES & OBESITY SCIENTIFIC MEETING, NEXT WEEK 16-19 SEPTEMBER IN VIENNA
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors...
PILA PHARMA: ALL H1 REPORT & INVESTOR INTERVIEWS NOW ONLINE
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors...
PILA PHARMA: H1 REPORT INTERVIEW RECORDING WITH DIREKT STUDIOS - CEO COMMENTS ON HEAVILY OVERSUBSCRIBED RIGHTS ISSUE AND PLANS
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors...
PILA PHARMA: CEO VISITS INVESTMENT PODCAST 10X TO COMMENT ON HEAVILY OVERSUBSCRIBED ISSUE (293,5%) AND OBESITY PLANS
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors...
REG
MAR
PILA PHARMA PUBLISHES INTERIM REPORT (1 JANUARY - 30 JUNE 2025)
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, today publishes t...
PILA PHARMA: INVITATION TO LIVE H1 REPORT INTERVIEW AND Q&A
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, invites sharehold...
PILA PHARMA ANNOUNCES THE COMPLETION OF REGISTRATION OF SHARES IN THE RIGHTS ISSUE AND ITS ASSOCIATED DIRECTED ISSUES, MARKING THE END OF THE RIGHTS ISSUE PROCESS
PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") announced on 23 July 2025 that the rights issue of units that was resolved by the board of directors, subject to the annual...
REG
PILA PHARMA announces updated dates for last day of trading with paid subscribed units and first day of trading in new shares
PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") announces that the last day of trading in paid subscribed units (Sw. BTU) in connection with the Company's rights issue of...
REG
The board of directors of PILA PHARMA has resolved to carry out a directed issue of units to underwriters in the previously ended rights issue
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEE...
REG
MAR
PILA PHARMA announces the outcome of its oversubscribed rights issue and resolves on a directed issue for over-allotment
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEE...
REG
THE LAST DAY OF SUBSCRIPTION OF UNITS IN PILA PHARMA'S RIGHTS ISSUE OF UNITS
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEE...
REG
THE LAST DAY OF TRADING IN UNIT RIGHTS IN PILA PHARMA'S RIGHTS ISSUE OF UNITS
Today, July 10, 2025, is the last day of trading in unit rights issued in connection with PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") rights issue of units which the B...
PILA PHARMA: INVESTMENT PODCAST GÖTT TJÖT OM AKTIER INTERVIEWS CEO ABOUT RIGHTS ISSUE AND OBESITY ASPIRATIONS
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, are delighted to...
PILA PHARMA: FINWIRE SIT-DOWN INTERVIEW TALKING FUNDRAISING AND BET ON OBESITY
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors...
PILA PHARMA: NEW INTERVIEW ON RIGHTS ISSUE AND BET ON OBESITY WITH DIREKT STUDIOS
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors...
CEO DISCUSSES ONGOING RIGHTS ISSUE AND BET ON OBESITY WITH INVESTMENT PODCAST 10X
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors...
REG
The subscription period in PILA PHARMA's rights issue of units begins today
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEE...
PILA PHARMA DISCUSSES ITS FINANCING ROUND WITH HELGE LARSEN & PROINVESTOR
PILA PHARMA AB (publ) (FN STO: PILA) has the pleasure to share with investors and others with interest in the Company or the general market, that PILA PHARMA has had another 1-on...
Om PILA PHARMA
Webbplats
pilapharma.com
Prenumerera
Få löpande information från PILA PHARMA via e-post.
Handelsinformation
Kurs ()
Förändring ()